HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.

Abstract
The neuropeptide melanocyte-inhibiting factor (MIF) or L-propyl-L-leucyl-glycinamide (PLG) has been reported in some studies to improve the motor signs of Parkinson's disease (PD) and in rodent models of PD. In this study of oral and intravenous MIF in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmosets, a wide range of doses of MIF administered alone (0.25, 1, 2, 5, 10, 20 mg/kg orally) did not increase locomotor activity, relieve motor disability, or induce dyskinesias. When MIF (1.0 and 5.0 mg/kg orally or 10 and 20 mg/kg intravenously) was administered concomitantly with levodopa/benserazide, no significant differences in motor function or dyskinesias were observed compared with levodopa/benserazide alone. The results of this first study of MIF in the marmoset MPTP model provide no encouragement for the reinvestigation of MIF in the clinical management of the motor signs of PD.
AuthorsRegina Katzenschlager, Michael J Jackson, Sarah Rose, Kim Stockwell, Kayhan A Tayarani-Binazir, Mohammed Zubair, Lance A Smith, Peter Jenner, Andrew J Lees
JournalMovement disorders : official journal of the Movement Disorder Society (Mov Disord) Vol. 22 Issue 5 Pg. 715-9 (Apr 15 2007) ISSN: 0885-3185 [Print] United States
PMID17373723 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiparkinson Agents
  • Levodopa
  • Benserazide
  • MSH Release-Inhibiting Hormone
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Topics
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Administration, Oral
  • Animals
  • Antiparkinson Agents (administration & dosage, toxicity)
  • Benserazide (administration & dosage, toxicity)
  • Callithrix
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Female
  • Infusions, Intravenous
  • Levodopa (administration & dosage, toxicity)
  • Locomotion (drug effects)
  • MSH Release-Inhibiting Hormone (administration & dosage, toxicity)
  • Male
  • Motor Activity (drug effects)
  • Parkinsonian Disorders (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: